Anti-IL-6R/PD-L1 bispecific antibody (Beijing Vdjbio)

抗IL-6R/PD-L1双特异性抗体（北京伟德杰生物）

Report date: 2025/06/04 15:13:24

Base Information

Drug NameAnti-IL-6R/PD-L1 bispecific antibody (Beijing Vdjbio)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Programmed death-ligand 1Interleukin-6 receptor alpha subunit antagonists
TargetsProgrammed death-ligand 1Interleukin-6 receptor alpha subunit
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Vdjbio Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Vdjbio Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A